Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results on March 11, 2020
March 05 2020 - 4:05PM
Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company
developing next-generation vaccines for serious infectious
diseases, today announced it will report its fourth quarter 2019
financial and operating results following the close of U.S.
financial markets on Wednesday, March 11, 2020.
Conference call
details are as follows: |
|
|
Date: |
March 11, 2020 |
Time: |
4:30 p.m. U.S. Eastern Time
(ET) |
Dial-in number: |
(877) 212-6076 (Domestic) or
(707) 287-9331 (International) |
Passcode: |
5695528 |
Webcast: |
www.novavax.com, “Investors”/
“Events” |
|
|
Conference call
and webcast replay: |
|
|
Dates: |
Starting at 7:30 p.m. ET,
March 11, 2020 until |
|
7:30 p.m. ET March 18,
2020 |
Dial-in number: |
(855) 859-2056 (Domestic) or
(404) 537-3406 (International) |
Passcode: |
5695528 |
Webcast: |
www.novavax.com, “Investors”/
“Events”, until June 11, 2020 |
About Novavax
Novavax, Inc. (Nasdaq:NVAX), is a late-stage
biotechnology company that promotes improved health globally
through the discovery, development, and commercialization of
innovative vaccines to prevent serious infectious diseases.
NanoFlu™, its quadrivalent influenza nanoparticle vaccine, is
currently in a pivotal Phase 3 clinical trial to address key
factors that can lead to the poor effectiveness of currently
approved flu vaccines. ResVax™, its RSV vaccine for infants via
maternal immunization, is the only vaccine to demonstrate efficacy
in a Phase 3 clinical trial. Novavax recently initiated development
of a vaccine program against COVID-19. Novavax is a leading
innovator of recombinant vaccines; its proprietary recombinant
technology platform combines the power and speed of genetic
engineering to efficiently produce a new class of highly
immunogenic nanoparticles addressing urgent global health
needs.
For more information, visit www.novavax.com and
connect with us on Twitter and LinkedIn.
Contacts:
InvestorsErika Trahanir@novavax.com240-268-2022
WestwickeJohn
Woolfordjohn.woolford@westwicke.com443-213-0506
MediaAmy Speakamy@speaklifescience.com617-420-2461
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From May 2024 to Jun 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Jun 2023 to Jun 2024